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A B S T R A C T
Background
Combination therapy (inhaled corticosteroids and long-acting beta2-agonists) and tiotropium are both used in the treatment of chronic
obstructive pulmonary disease (COPD). There is uncertainty about the relative benefits and harms of these treatments.
Objectives
To assess the relative effects of inhaled combination therapy and tiotropium on patients with COPD.
Search methods
We searched the Cochrane Airways Group Specialised Register of trials (March 2010) and reference lists of articles. We also contacted
authors of the studies.
Selection criteria
We included only parallel, randomised controlled trials comparing inhaled combination corticosteroid and long-acting beta2-agonist
against inhaled tiotropium bromide.
Data collection and analysis
Two authors independently assessed trials for inclusion and then extracted data on trial quality and outcome results. We contacted
study authors for additional information. Discrepancies were resolved through discussion.
Main results
One large two year trial (INSPIRE) and two smaller, shorter trials (Dawber 2005; SCO40034) were found. The results from these
trials were not pooled. The number of withdrawals from each arm of the INSPIRE trial was large and imbalanced and outcome data
was not collected for patients who withdrew, raising concerns about the reliability of data from this study.
In INSPIRE, there were more deaths on tiotropium than on fluticasone/salmeterol (Peto OR 0.55; 95% CI 0.33 to 0.93). This was a
statistically significant difference, however the number of withdrawals from each of the arms was eleven times larger than the observed
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number of deaths for participants on fluticasone/salmeterol and seven times larger for participants on tiotropium. There were more
all cause hospital admissions in patents on fluticasone/salmeterol than those on tiotropium in INSPIRE (Peto OR 1.32; 95% CI
1.04 to 1.67). There was no statistically significant difference in hospital admissions due to exacerbations, the primary outcome of
INSPIRE. There was no significant difference in exacerbations in patients on fluticasone/salmeterol compared to tiotropium when
compared as either an odds ratio or a rate ratio (mean number of exacerbations per patient per year). Exacerbations requiring treatment
with oral corticosteroids were less frequent in patients on fluticasone/salmeterol (Rate Ratio 0.81; 95% CI 0.67 to 0.99). Conversely
exacerbations requiring treatment with antibiotics were more frequent in patients treated with fluticasone/salmeterol (Rate Ratio 1.19;
95% CI 1.02 to 1.38). There were more cases of pneumonia in patients on fluticasone/salmeterol than those on tiotropium (Peto OR
2.13; 95% CI 1.33 to 3.40). Confidence intervals for these outcomes do not reflect the additional uncertainty arising from unknown
outcome data for patients who withdrew.
Authors’ conclusions
Since the proportion of missing outcome data compared to the observed outcome data is enough to induce a clinically relevant bias
in the intervention effect, the relative efficacy and safety of combined inhalers and tiotropium remains uncertain. Further large, long-
term randomised controlled trials comparing combination therapy to tiotropium are required, including adequate follow-up of all
participants randomised (similar to the procedures undertaken in TORCH and UPLIFT). Additional studies comparing alternative
inhaled LABA/steroid combination therapies with tiotropium are also required.
P L A I N L A N G U A G E S U M M A R Y
Combined inhalers compared to tiotropium inhalers for the treatment of chronic obstructive pulmonary disease
Chronic Obstructive Pulmonary Disease (COPD) is a general term referring to chronic bronchitis and emphysema, or both. COPD
occurs when airflow to the lungs is restricted. Symptoms include cough and breathlessness and inhalers are commonly used to prevent
and relieve these symptoms. COPD is usually caused by smoking and the best way to improve symptoms is to give up smoking.
COPD trials lasting longer than six months often have large numbers of people leaving the trial early. In INSPIRE, the largest trial in
our review comparing fluticasone/salmeterol to tiotropium, there were seven to eleven times more people leaving the trial early than the
number who died; a number that swamps the death rate. Therefore we felt unable to draw a reliable conclusion as to which treatment
has the lowest mortality rate. This uncertainty also left us unable to reliably say which drug was better in terms of reducing COPD
exacerbations, hospitalisations, serious adverse events or improving quality of life and health status.
More information about COPD and explanations of terms used in this summary can be found here
B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is characterised
by chronic airflow limitation, limited response to short-acting
beta2-agonists, and is associated with a smoking history (GOLD).
Symptoms of COPD include breathlessness and impaired exercise
capacity. There are a number of commonly used pharmacologi-
cal treatments in COPD management including inhaled short-
acting beta-agonists (SABA), long-acting beta2-agonists (LABA)
(Appleton 2006a), inhaled corticosteroids (ICS) (Yang 2007) and
anticholinergics such as tiotropium (Barr 2005) and ipratropium
bromide (Appleton 2006b; Appleton 2006c). Self-management
education and pulmonary rehabilitation should accompany these
pharmacological interventions (Effing 2007; Lacasse 2006).
Description of the intervention
Combination therapy is a maintenance inhaler that delivers an in-
haled corticosteroid and a long-acting beta-agonist concurrently
at the same dose. Combination therapy is currently available as
combination fluticasone and salmeterol (marketed as Seretide or
Advair, GSK) and budesonide and formoterol (marketed as Sym-
bicort, AstraZeneca). Both combination products are licensed for
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use in COPD at the highest doses of ICS (daily dose fluticasone
1,000 µg and budesonide 800 µg). Inhaled corticosteroids are
anti-inflammatories and long-acting beta-agonists cause smooth
muscle relaxation resulting in bronchodilation.
Tiotropium bromide (marketed as ’Spiriva’, Boehringer Ingel-
heim) is an inhaled long-acting anticholinergic agent, and has
gained widespread acceptance as a maintenance therapy in COPD
(Barr 2005; GOLD; UPLIFT). Tiotriopium is a long-acting anti-
cholinergic agent that targets bronchospasm in COPD by relaxing
airway smooth muscle.
Why it is important to do this review
Both tiotropium and combination inhalers have been shown to
improve key clinical indicators of disease in clinical trials against
placebo.
Combination therapy has been shown to reduce exacerbations,
mortality and to improve health status compared to placebo
(Nannini 2007a). Inhaled corticosteroids alone have been shown
to reduce COPD exacerbations (Yang 2007). Long-acting beta-
agonists have also been shown to reduce exacerbations and im-
prove lung function (Appleton 2006a). The effects of combina-
tion treatment against component monotherapy are more variable
(Nannini 2007b; Nannini 2007c). However, concerns have been
raised about the risk of pneumonia associated with ICS in COPD
patients (Singh 2009).
Benefits of tiotropium in comparison with placebo include re-
duced exacerbations and related hospital admissions, and im-
provements in quality of life and lung function (Barr 2005;
UPLIFT). However, in the UPLIFT trial conducted over four
years tiotropium did not slow the rate of decline in FEV1 com-
pared with placebo (UPLIFT). Concerns that inhaled anticholin-
ergics increase the long-term risk of major cardiovascular events
in COPD have been raised (Singh 2008b), but this was not found
in UPLIFT.
This leaves clinicians and patients facing uncertainty as to the
relative merits of these treatments, and how the side-effect profiles
of each compare.
O B J E C T I V E S
To compare the relative effects of inhaled combination therapy
and tiotropium on markers of exacerbations, symptoms, quality
of life, lung function, pneumonia and serious adverse events in
patients with chronic obstructive pulmonary disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials with a parallel
group design comparing the interventions. Studies were not ex-
cluded on the basis of blinding.
Types of participants
Populations with a diagnosis of chronic obstructive pulmonary
disease. We only included studies where an external set of crite-
ria had been used to screen participants for this condition (e.g.
GOLD, ATS, BTS, TSANZ).
Types of interventions
1. Inhaled combination corticosteroid and long-acting beta2-
agonist (such as fluticasone/salmeterol, budesonide/formoterol,
beclomethasone/formoterol).
2. Inhaled tiotropium bromide
Types of outcome measures
Primary outcomes
1. Mortality (all cause)
2. Hospital admission
3. Exacerbations; all cause, requiring short courses of oral
corticosteroids or antibiotics as defined by agreed criteria
4. Pneumonia
Secondary outcomes
1. Quality of life (measured with a validated scale for COPD,
e.g. St George’s Respiratory Questionnaire, Chronic Respiratory
Disease Questionnaire)
2. Symptoms
3. Forced expiratory volume in one second (FEV1)
4. Non-fatal serious adverse events
5. Adverse events
6. Withdrawals
Search methods for identification of studies
Electronic searches
We identified trials using theCochrane Airways Group Specialised
Register of trials, which is derived from systematic searches of
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bibliographic databases including the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL), MEDLINE, EMBASE,
CINAHL, AMED, and PsycINFO, and handsearching of res-
piratory journals and meeting abstracts (see the Airways Group
Module for further details). All records in the Specialised Register
coded as ’COPD’ were searched using the following terms:
(tiotropium or spiriva) AND (((budesonide or fluticasone or be-
clomethasone or mometasone or steroid* or corticosteroid*) and
(formoterol or salmeterol or indacterol or (beta* and agonist*)))
or (symbicort or viani or seretide or advair or foster or fostair or
inuvair or combination*))
The search was conducted in March 2010.
Searching other resources
We reviewed reference lists of all primary studies and review arti-
cles for additional references. We contacted authors of identified
trials and manufacturers to ask if they knew of other published or
unpublished studies.
Data collection and analysis
Selection of studies
Two review authors (EJW and CJC) screened the titles and ab-
stracts of citations retrieved through literature searches and ob-
tained full papers of references deemed to be potentially relevant.
We assigned each reference to a study identifier and assessed them
against the inclusion criteria of the review.
Data extraction and management
We extracted characteristics and data for studies that met the eligi-
bility criteria of the review using a dedicated extraction sheet. The
extraction of characteristics and data was performed in duplicate,
and discrepancies were identified and resolved through discussion.
Assessment of risk of bias in included studies
We assessed the risk of bias according to recommendations out-
lined in Cochrane Handbook for the following items:
1. Allocation sequence generation
2. Concealment of allocation
3. Blinding of participants and investigators
4. Handling of missing data
Each potential source of bias was graded as yes, no or unclear,
relating towhether the potential for bias was low, high or unknown
respectively.
Measures of treatment effect
We intended to combine dichotomous data variables (such as
mortality, pneumonia and study withdrawal) as Peto Odds Ra-
tios (OR) with 95% confidence intervals as this is more suitable
than Maentel-Haenszel for rare events. However, the events in
INSPIREwere not rare.We cross-checked all the PetoOddsRatios
with the Maentel-Haenszel Odds Ratios and found no difference,
so we reported the Peto Odds Ratio as per protocol. We planned
to combine continuous outcome data (such as symptoms, quality
of life and FEV1) as fixed effect mean differences with 95% confi-
dence intervals. In INSPIRE, exacerbations were reported as rate
ratios (RR), and we entered these data into RevMan 5.0 using the
GIV function.
Unit of analysis issues
Data on exacerbations were provided by INSPIRE trialists as the
difference in exacerbation rates between patients on fluticasone/
salmeterol and those on tiotropium, and were based on rate ratios
using negative binomial model estimates and 95% confidence in-
tervals. The natural log of the rate ratio along with the standard
error calculated from the confidence interval were entered into
RevMan 5.0 using the GIV function and the resulting confidence
intervals were cross-checked with those provided by INSPIRE for
exacerbations.
Data for quality of life and FEV1 were calculated as a mean differ-
ence with 95% confidence intervals. We entered the mean differ-
ence and standard errors calculated from 95% confidence intervals
into RevMan 5.0 and analysed it using the GIV tool in RevMan
5.0.
Dealing with missing data
We contacted investigators or study sponsors in order to verify key
study characteristics and to obtain missing numerical data.
Assessment of heterogeneity
We planned to assess the amount of statistical variation between
the study results with the I2 measurement.
Data synthesis
We planned to calculate numbers needed to treat from the pooled
Odds Ratio and its confidence interval, and apply them to appro-
priate levels of baseline risk.
We intended to present the findings of our four primary outcomes
(mortality, hospital admission, exacerbations and pneumonia) in
a summary of findings table generated using GradePro software.
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Subgroup analysis and investigation of heterogeneity
We planned to subgroup studies according to:
1. Type and dose of combination therapy
2. Severity of disease at baseline
Sensitivity analysis
We intended to assess the sensitivity of our primary outcomes
to degree of bias. We planned to compare the Peto Odds Ratio
results for dichotomous outcomeswithMantel-Haenszel fixed and
random models and with the pooled risk differences.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
See Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
The initial search was carried out in October 2009 and identi-
fied 81 references. Of these 13 were potentially relevant and were
obtained in full text for further assessment. Eight of these full
text documents were eligible and belonged to three included stud-
ies (Dawber 2005; INSPIRE; SCO40034). A further report on
Dawber 2005 was identified from the GlaxoSmithKline (GSK)
trial register. We asked five trialists if they knew of any other pub-
lished and unpublished trials; there were five responses but no rel-
evant studies that had not already been located by the search were
identified. Eight further references were returned by an updated
search in March 2010, but none of these was eligible.
Included studies
Participants
A total of 1507 participants were recruited into the three eli-
gible studies (Dawber 2005; INSPIRE; SCO40034). INSPIRE
was by far the largest included trial, with 1,323 participants,
whilst Dawber 2005 had 59 and SCO40034 had 125 participants.
INSPIREwas a two year trial whilstDawber 2005 and SCO40034
were much shorter at three and twelve weeks respectively. Owing
to the disparity in the trial lengths and because the primary focus
of our review was on long-term outcomes, we did not pool the
results of the trials. This review therefore focusses primarily on the
results of INSPIRE.
Patients in INSPIRE were classified as having GOLD stage III
(FEV1 ≥30 to <50% predicted) or GOLD stage IV (FEV1 <30%
predicted). There were N = 540 patients with stage III COPD on
fluticasone/salmeterol with a mean FEV1 of 1.09 L and N = 537
patients with a mean FEV1 of 1.11 L on tiotropium. There were
N = 100 patients with stage IV COPD on fluticasone/salmeterol
with a mean FEV1 of 0.73 L and N = 101 patient with a mean
FEV1 of 0.71 L on tiotropium. In INSPIRE, 48% of participants
in the fluticasone/salmeterol arm and 51% in the tiotropium arm
stopped taking inhaled corticosteroids at baseline. All participants
had a smoking history of greater than 10 pack years.
Interventions
Patients recruited to INSPIRE received either fluticasone/salme-
terol (500/50 µg twice a day) as a dry powder via a DISKUS or
Accuhaler inhaler or tiotropium (18 µg once a day) delivered via
a dry-powder Handihaler.
Participants in INSPIRE were allowed to take short-acting
beta2-agonists and short courses of oral corticosteroids alongside
their study medications. Prior to randomisation, participants in
INSPIRE were given oral prednisolone (30 mg) once a day and
inhaled fluticasone/salmeterol (500/50 µg) twice a day during a
two week run-in period.
Outcomes
The primary outcomes varied between the studies and were dif-
ferent from our primary outcomes. The primary outcome for
INSPIRE was the rate of health care utilisation for COPD exacer-
bations, which we incorporated in to our review. The primary out-
come assessed by Dawber 2005 was mucociliary clearance rate ex-
pressed as the percent particle retention at 2.5 hours. SCO40034
was an exploratory study to compare the clinical efficacy of fluti-
casone/salmeterol against tiotropium and therefore did not define
a primary outcome.
Excluded studies
A total of four studies failed to meet the eligibility criteria for
the review (see Characteristics of excluded studies). Three trials
(Golabi 2006; Hara 2007; Singh 2008) were excluded because
they were crossover trials, which are not suitable for assessing long-
term outcomes.
One trial (Bateman 2008) was excluded because the intervention
compared fluticasone (250 µg) and salmeterol (50 µg) adminis-
tered via separate metered dose inhalers to tiotropium (18 µg).
We felt that this could lead to discrepancies in the analysis if par-
ticipants stopped taking one inhaler and continued taking the
other. This randomised, double-blind, triple-dummy pilot study
administered fluticasone and salmeterol to 51 participants and
tiotropium to 56 participants. The participants had moderate or
severe COPD and a smoking history of greater than 10 pack years
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although the baseline characteristics were not comparable across
both arms. The primary outcome was FEV1 and there was no sig-
nificant difference in the lung function or occurrence of adverse
effects between the two intervention arms after 43 days and there
was a single dropout in the fluticasone/salmeterol arm.
Risk of bias in included studies
An assessment of the risk of bias is presented in the Characteristics
of included studies table and summarised in a risk of bias table
(Figure 1).
Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
INSPIRE reported adequate sequence generation and allocation
concealment. Dawber 2005 and SCO40034 did not report full
details in the study reports, but GSK supplied unpublished in-
formation describing adequate computerised randomisation and
allocation on request.
Blinding
All three trials were blinded by employing a double-dummy de-
sign; the two drugs were administered via different types of in-
haler, each participant was given two inhalers to use each day, one
containing the intervention medication and a second containing
placebo. Neither the patient nor the investigator knew what med-
ication a particular participant was randomised to.
Incomplete outcome data
INSPIRE suffered from high withdrawal rates, and data were
not collected for patients who withdrew. For a discussion of the
methodological issues affecting COPD trials see Discussion.
Selective reporting
All three trials adequately reported outcome data for the primary
and secondary outcomes that they had pre-specified in the study
record.
Effects of interventions
Primary outcome: Mortality (all cause)
In INSPIRE, there were more deaths on tiotropium (38/665 peo-
ple) than on fluticasone/salmeterol (21/658) (Peto OR 0.55; 95%
CI 0.33 to 0.93). Although this was a statistically significant dif-
ference, the number of withdrawals from each of the arms was
eleven times larger than the number of deaths for participants on
fluticasone/salmeterol and seven times larger for participants on
tiotropium. This uncertainty about the results is not reflected in
the confidence interval for the odds ratio.
Primary outcome: Hospital admission
There were more all cause hospital admissions in patents on fluti-
casone/salmeterol (215/658) than those on tiotropium (179/665)
in INSPIRE (Peto OR 1.32; 95% CI 1.04 to 1.67). The primary
outcome of INSPIRE was hospital admissions due to exacerba-
tions. More patients on salmeterol/fluticasone were hospitalised
due to exacerbations (105/658) compared to tiotropium (86/665)
(PetoOR1.28; 95%CI 0.94 to 1.74), but this was not statistically
significant.
Primary outcome: Exacerbations
Data for all cause exacerbations was reported as both count data
and as a rate (i.e. the mean number of exacerbations per year) in
INSPIRE. The differences between these methods of analysis are
discussed in the Summary of main results.
Firstly, looking at the number of people experiencing one or more
exacerbations. There was no significant difference in the number
of people experiencing one or more exacerbations, (408/658 in
the fluticasone/salmeterol arm versus 393/665 in the tiotropium
arm; Analysis 1.3).
The number of exacerbations was also reported as the mean num-
ber of events per year. There was no significant difference in exac-
erbations of any type in patients on fluticasone/salmeterol com-
pared to tiotropium (RR 0.97; 95% CI 0.84 to 1.12; Analysis
1.4). Overall 62% of the fluticasone/salmeterol group and 59%
of the tiotropium group had one or more exacerbation requiring
therapeutic intervention and the trialists estimated this to equate
to 1.28 and 1.32 exacerbation per year for patients on fluticasone/
salmeterol and tiotropium respectively. Exacerbations requiring
treatment with oral corticosteroids were more frequent in patients
on tiotropium (RR 0.81; 95% CI 0.67 to 0.99) and conversely
exacerbations requiring treatment with antibiotics were more fre-
quent in patients treated with fluticasone/salmeterol (RR 1.19;
95% CI 1.02 to 1.38).
Primary outcome: Pneumonia
There were more cases of pneumonia in patients on fluticasone/
salmeterol (50/658) than in those on tiotropium (24/665) (Peto
OR 2.13; 95% CI 1.33 to 3.40). There were several figures re-
ported for pneumonia in the INSPIRE trial (see Table 1) all of
which indicated that thereweremore cases of pneumonia in partic-
ipants on fluticasone/salmeterol compared to those on tiotropium.
While this is statistically significant, there is considerable uncer-
tainty over the clinical interpretation of this result owing to the
large drop out rates. Moreover, if this is a true finding, the higher
pneumonia rate in the combination group was not associated with
a significant increase in exacerbations, hospitalisations due to ex-
acerbations or deaths.
Secondary outcome: Quality of life
Patients on fluticasone/salmeterol reported better quality of life
than those on tiotropium at two years from baseline (MD -2.07;
95% CI -4.02 to -0.12). In real terms, this meant that patients
on salmeterol/fluticasone reported amean improvement in quality
of life of 1.7 units on the St. Georges Respiratory Questionnaire
(SGRQ) whilst those on tiotropium reported amean worsening in
their quality of life of 0.4 units. Theminimumclinically important
difference in quality of life measured on the SGRQ is four units.
INSPIRE reported that 35% of patients on fluticasone/salmeterol
and 27% patients on tiotropium (OR 1.29; 95% CI 1.04 to 1.60)
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experienced an improvement in quality of life of≥four units. Data
for the number of patients who had a deterioration in quality of
life of ≥four units was not reported (Jones 2009).
Secondary outcome: Forced expiratory volume in one
second (FEV1)
FEV1 data were available at a number of time points in INSPIRE
and therefore data were entered at both eight weeks and two
years. At eight weeks, FEV1 had increased by 0.04 L (± 0.010)
from baseline in patients on fluticasone/salmeterol, whilst those
on tiotropium had an increase of 0.06 L (± 0.010). There was no
statistically significant between group difference (MD -0.02; 95%
CI -0.05 to 0.01). At two years, the FEV1 of patients on fluti-
casone/salmeterol had decreased by -0.01 L (± 0.012) compared
to baseline whilst those on tiotropium showed an improvement
compared to baseline of FEV1 0.01 L (± 0.013), again not a statis-
tically significant between group difference (MD -0.02; 95% CI
-0.05 to 0.01).
Secondary outcome: Serious adverse events (Non-fatal)
There were more serious adverse events in patients on fluticasone/
salmeterol (194/658) than in patients on tiotropium (141/665)
(Peto OR 1.55; 95% CI 1.21 to 1.98) in INSPIRE.
Secondary outcome: Adverse events
In INSPIRE there were fewer adverse events among patients on
fluticasone/salmeterol (435/658) than tiotropium (414/665) (Peto
OR 1.18; 95% CI 0.94 to 1.48).
Secondary outcome: Withdrawal
There were large numbers of withdrawals from INSPIRE and the
withdrawal rate was higher in the tiotropium group than in the
fluticasone/salmeterol group. There were fewer withdrawals for
any reason for patients on fluticasone/salmeterol (232/658, 35%)
compared with tiotropium (279/665, 42%) (Peto OR 0.75; 95%
CI 0.60 to 0.94). The difference between the number withdraw-
ing due to adverse events (Peto OR 1.03; 95% CI 0.72 to 1.47)
and lack of efficacy (Peto OR 0.84; 95% CI 0.52 to 1.37) was
not statistically significant. The INSPIRE trialists reported reasons
for withdrawal (Table 2) and this demonstrated that the greatest
difference was higher rates of withdrawal due to COPD exacer-
bations in patients on tiotropium than in those on fluticasone/
salmeterol.
There were no data reported for symptoms.
Summary of results for Dawber 2005 and SCO40034
There were no deaths in eitherDawber 2005 or SCO40034. There
was no significant difference in hospital admissions, cases of pneu-
monia, FEV1, serious adverse events or adverse events in either
Dawber 2005 or SCO40034. There were more withdrawals in
patients on tiotropium compared to fluticasone/salmeterol in pa-
tients in the SCO40034 trial.
D I S C U S S I O N
Methodological issues in COPD trials
Withdrawal rates in COPD trials are commonly high, especially in
studies longer than six months in duration. There is no consensus
on how to handle participants for whom data is not available (
Cochrane Handbook). There are two available options: intention-
to-treat analysis, or available case analysis.
The principles of intention-to-treat analyses are that participants
are analysed according to the intervention group to which they
were initially randomised regardless of the treatment received.
Outcome data are recorded for all participants, and all randomised
participants are included in the analysis. Performing analyses on
a true intention-to-treat basis when outcome data for all partici-
pants is missing is not possible. To perform an intention-to-treat
analysis regardless of the missing data does not take into account
participants who withdraw and gives an overly precise estimate of
the treatment effect. When withdrawals are related to the treat-
ment (i.e. not at random), the participants whowithdraw are likely
to have poorer outcomes than those who remain in the trial and
provide data (Suissa 2008). This can lead to a ’healthy survivor’
effect.
One way to deal with missing outcome data due to withdrawals is
imputation, and there are three ways of estimating missing values.
One approach is to assume that the rate of events in the partici-
pants who withdraw occurs at the same rate as it does in those who
remained in the study and provide data. This increases the preci-
sion of the estimate of the confidence intervals, but if the assumed
rate of events is incorrect, the effect estimate for the study will be
biased. A second option is to simulate best-case worst-case scenar-
ios, where it is assumed that all the participants who withdrew on
one intervention arm experienced the event and then repeat the
analysis with the other intervention arm, comparing the results
as a sensitivity analysis. This is problematic when the number of
dropouts is significantly greater than the numbers of patients ex-
periencing the event in the study. The third way is to assume that
the rates of events in the withdrawals is similar to those observed
in other similar trials.
However, full follow-up of patients that withdraw can introduce a
different bias. Patients that withdraw are likely to begin treatment
with another medication, but their outcomes are still attributed
to the treatment group to which they were randomised. This is
particularly problematic in head-to-head studies because patients
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often go onto the other study medication, which could potentially
provide an inaccurate estimate of the true difference between the
treatments.
Availiable case analysis, where treatment effect is based on the
number of participants who provided data, does not take into
account the outcomes of those who withdrew.
COPD patients who withdraw early tend to be sicker at recruit-
ment and deteriorate faster than those who remain in the study.
Additionally, because COPD is a chronic condition, many pa-
tients are already taking medication when they start a clinical trial
and withdrawal symptoms can occur (Suissa 2008). In effect a trial
can be looking at the effect of withdrawing an existing treatment
as well as introducing a new one.
Participants in COPD trials are usually already taking medication
for their condition before entry. Run-in periods, where partici-
pants take a standard treatment for a few weeks prior to randomi-
sation were designed to account for the improvement in health
status that comes at the start of a trial due to increased medical
attention (Calverley 2003). However, these run-in periods limit
the overall applicability of the results if the outcomes were affected
by the run-in drugs, but attributed to the study medication (Suissa
2008a).
Summary of main results
The number of withdrawals from both arms of the INSPIRE trial
was large and outcome data were not collected for patients who
withdrew. It is feasible to record mortality data (vital status) for
participants who withdrew, but not reasonably possible to obtain
data for other outcomes. Because outcome data for those who
withdrew were not available, the confidence intervals for the out-
comes do not reflect this additional uncertainty. We cannot be
sure that the mortality rate for patients who withdrew on either
drug was higher, lower or the same as those who completed the
study. It would be, in our opinion, inappropriate to apply simple
imputation of data in this instance.
When patients withdraw from a study for reasons relating to out-
comes, the perceived benefit (or lack thereof ) of a study drug
can have great influence over their decision to remain in the trial
(Kesten 2007). Kesten 2007 reported higher incidence rates of
death following premature discontinuation of study medication.
INSPIRE trialists cited the differential withdrawal rate as an indi-
rect marker of treatment efficacy. There was no significant differ-
ence in the withdrawals due to lack of efficacy or adverse events
in INSPIRE although more people on tiotropium withdrew com-
pared to those on fluticasone/salmeterol overall. The proportion
of missing outcome data compared to the observed outcome data
is enough to induce a clinically relevant bias in the intervention
effect.
We presented exacerbations using two different units of analysis
in this review. There are several ways to analyse exacerbation rates
and each is associated with advantages or disadvantages (Keene
2008). Looking at the number of patients experiencing one or
more exacerbations does not give any information about exacerba-
tion frequency in the same patent and does not take into account
duration of study (Keene 2008; Karner 2011). You therefore get
different information from the number of people experiencing one
or more exacerbations and the mean number of exacerbations per
year.While neither of the methods of reporting all cause exacerba-
tions resulted in a statistically significant difference, it is interest-
ing to note that the direction of the treatment effect is different.
Reported as number of people experiencing one or more exacer-
bations, there are fewer exacerbations in people on tiotropium.
However looking at the relative rate, there are fewer exacerbations
per year in patients on fluticasone/salmeterol. This may represent
the play of chance, but we cannot rule out the possibility that the
two treatments have different impacts on patients with occasional
or frequent exacerbations.
Quality of the evidence
All three trials had adequate sequence generation, allocation con-
cealment and blinding. Additionally, data was provided for the
outcomes outlined in the protocols of the trials. The principal
concern with the largest study addressing the review question,
INSPIRE, relates to the handling of data from participants who
withdrew.
Potential biases in the review process
We minimised bias in our search process thorough using compre-
hensive search terms and asking authors to identify other pub-
lished an non-published studies. Studies were determined as in-
cluded or excluded, data was extracted and risk of bias attributed
in duplicate to minimise error.
Agreements and disagreements with other
studies or reviews
Previous systematic reviews evaluating combined inhalers com-
pared to placebo (Nannini 2007a) and combined inhalers com-
pared to long-acting beta2-agonists (Nannini 2007b) have shown
an elevated risk of pneumoniawith combination therapy, (seeTable
3). There were relatively more cases of pneumonia reported in
these systematic reviews (which included TORCH) and TORCH
than were recorded in INSPIRE.
There were relatively fewer deaths in INSPIRE compared to
TORCH that included complete follow up of vital status for par-
ticipants who withdrew; 1.6% per year in INSPIRE compared to
4.2% per year in TORCH. There may have been at least as many
deaths in patients who withdrew from INSPIRE as in those who
completed the trial.
Indirect comparison
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There are two Cochrane reviews that may serve as a useful indirect
comparison of treatment efficacy; combination inhaled steroids
and long-acting beta-agonists versus placebo (Nannini 2007a) and
tiotropium versus placebo (Barr 2005). We include the following
descriptions for comparison only and have not calculated an esti-
mate of relative benefits and harms from these meta-analyses.
Nannini 2007a reported outcomes for a total of 6427 participants
in 11 studies. Two studies compared budesonide/formoterol, while
the remaining studies compared fluticasone/salmeterol albeit at
different doses. The meta-analysis was dominated by the largest
trial TORCH which had complete follow up for vital status of all
participants. All cause mortality was reduced in patients on com-
bined inhalers compared to placebo (OR 0.79 (95% CI 0.65 to
0.96)). Exacerbations were less frequent in participants on com-
bined inhalers (rate ratio 0.74 (95%CI 0.7 to 0.8)) and an increase
in the risk of pneumonia was noted in the groups that received
inhaled steroids either alone or in combination.
Barr 2005 reported outcomes for a total of 6584 participants across
nine studies, comparing tiotropium to placebo, ipratropium or
long-acting beta2-agonist. All cause mortality was reduced in par-
ticipants on tiotropium compared to placebo (OR 0.73 (95% CI
0.35 to 1.49) and COPD exacerbations were also reduced (OR
0.75 (95%CI 0.66 to 0.85)). The only adverse event data available
to pool was for dry mouth which was more frequently experienced
by patients randomised to tiotropium than placebo.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
INSPIRE had a high and unbalanced withdrawal rate. The pro-
portion of missing outcome data compared to the observed out-
come data is enough to induce a clinically relevant bias in the
intervention effect. The relative efficacy and safety of combined
inhalers and tiotropium remains uncertain.
Implications for research
Further large, long-term randomised controlled trials comparing
combination therapy to tiotropium are required including follow-
up of all participants randomised (similar to TORCH and UP-
LIFT). Additional studies comparing alternative inhaled LABA/
steroid combination therapies with tiotropium are also required.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Dawber 2005
Methods Design: A single centre, randomised, double-blind, double dummy, parallel group study
over three weeks from March to May 2004 in Germany
Run-in: Two weeks. Subjects discontinued their usual COPDmedications. Participants
were given inhaled salbutamol VENTOLIN as a relief medication with a VOLUMATIC
spacer device
Participants Population: 59 Adults with a clinical history of moderate or severe COPD (30% ≤
FEV1 > 80% predicted normal)
Baseline Characteristics: Mean age 59 years.
Inclusion Criteria: Smoking history of ≥ 10 pack years. Females of child-bearing po-
tential were required to use adequate birth control methods
Exclusion Criteria: FEV1 > 70% predicted normal at baseline. Participants that were
unable to complete daily record card during run-in period or demonstrate correct use of
inhaler
All subjects received salbutamol as a relief medication delivered via a MDI and spacer
Interventions 1. Combination of fluticasone 500 µg and salmeterol 50 µg twice a day via DISKUS
inhaler plus placebo capsules to match TIO delivered once daily via the Handihaler
inhaler.
2. Tiotropium 18 µg once a day via Handihaler plus placebo to match FPS
DISKUS combination product delivered twice daily.
Outcomes Primary Outcome: mucociliary clearance rate (PPR2.5).
Secondary outcomes include: mucociliary clearance rate (PPR4); mucociliary clearance
as measured by the half life of the fast clearance slope; FEV1, FVC, Raw, PEF, COPD
symptoms.
Notes Sponsored by GlaxoSmithKline.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Subjects were assigned to study treat-
ment in accordance with the randomisa-
tion schedule, which was generated, using
the GSK computer programme Patient Al-
location for Clinical Trials (PACT).”
Allocation concealment (selection bias) Low risk “Subjects were assigned to study treat-
ment in accordance with the randomisa-
tion schedule, which was generated, using
the GSK computer programme Patient Al-
location for Clinical Trials (PACT).”
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Dawber 2005 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind double dummy.”
The active tiotropium bromide capsules
and the placebo capsules were notice-
ably different so returned medication was
logged by someone not directly involved in
the study
Unblinding was permitted only for clini-
cal management, welfare of the subject or
for serious adverse events and GSK were
not notified of the withdrawee’s treatment
allocation. Decisions to withdraw subjects
due to adverse events were made before un-
blinding
“Neither the subject nor the investigator
knew which treatment had been assigned
to each subject. The investigator was, how-
ever, supplied with a sealed envelope con-
taining the code break for the subjects for
emergency use.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk One dropout due to adverse effects in a
drug already on the market
INSPIRE
Methods Design: A randomised, double-blind, double-dummy,multi-centre, parallel-group study
over 104 weeks from June 2003 to February 2006 at 173 centres in 20 European coun-
tries. (Austria, Belgium, Czech Republic, Denmark, Estonia, Germany, Greece, Italy,
Latvia, Lithuania, Netherlands, Norway, Romania, Russia, Slovak Republic, Slovenia,
Spain, Sweden, Ukraine and the UK)
Run-in: Two weeks on oral prednisolone and salmeterol.
Participants Population: 1,323 adults with a clinical history of severe and very severe COPD (GOLD
stage III and IV). FEV1 less than 50% for inclusion into the trial.
Baseline Characteristics: Mean age 64 years. FEV1 39% predicted. Inhaled corticos-
teroids used previously by 50% of participants. Exacerbation in previous 12 months in
86% of participants. 48% of participants on FPS and 51% on tiotropium stopped taking
inhaled corticosteroids at baseline
Inclusion Criteria: Aged 40 to 80 years, with a smoking history of 10 or more pack-
years, a clinical history of COPD exacerbations, post-bronchodilator FEV1 less than
50% of predicted, bronchodilator reversibility of less than 10% in FEV1 to 400 mg
salbutamol, score of 2 or more on theModified Medical Research Council dyspnea scale.
Exclusion Criteria: Asthma or atopic disease, a lung disease likely to confound the drug
response other than COPD, a recent exacerbation (within 6 weeks of screening or during
run-in); receiving long-term oxygen therapy or pulmonary rehabilitation or had a known
or suspected hypersensitivity to beta2-agonists, inhaled corticosteroids, anticholinergic
agents or any components of these formulations
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INSPIRE (Continued)
Interventions 1. Combination of fluticasone 500 µg and salmeterol 50 µg twice a day via
DISKUS/ACCUHALER inhaler plus placebo capsules to match TIO delivered once
daily via the Handihaler inhaler.
2. Tiotropium 18 µg once a day via Handihaler plus placebo to match FPS
DISKUS/ACCUHALER combination product delivered twice daily.
Outcomes Primary outcome: To compare the rate of health care utilization (HCU) COPD exacer-
bations in those using fluticasone/salmeterol (500/50 µg) versus those using tiotropium
18 µg
Notes Sponsored by GlaxoSmithKline.
Participants were allowed to use short-acting inhaled beta2-agonists and standardised
short courses of oral corticosteroids
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated central randomisa-
tion list. Stratified allocation by centre and
smoking. Block size of four
Allocation concealment (selection bias) Low risk Telephone interactive voice response sys-
tem.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind, double dummy design.
Due to a difference in appearance between
tiotropium bromide and placebo inhala-
tion capsules, study medication was dis-
pensed by someone not directly involved in
trial. Neither the investigator nor site per-
sonnel were present when the subject ad-
ministered his/her study medication. Sub-
jects were instructed not to show their
study medication to other subjects. De-
cisions to withdraw subjects due to ad-
verse events were made before unblinding.
Subjects were unblinded only in emergen-
cies where knowledge of the investigational
product was essential for the clinical man-
agement or welfare of the subject. Emer-
gency unblinding was done via an auto-
mated telephone system.
Incomplete outcome data (attrition bias)
All outcomes
High risk On FPS 35%withdrew from the study and
on tiotropium42%withdrew. Trialists pro-
vided an adequate breakdownof reasons for
withdrawal. Differential withdrawal rates
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INSPIRE (Continued)
in the two arms may have introduced bias
into all the outcome assessments
SCO40034
Methods Design: A randomised, double-blind, double-dummy, multi-centre, parallel-group ex-
ploratory study over 12 weeks from March 2003 to October 2003 at 17 centres in the
Netherlands
Run in: All oral, slow-release and long-acting beta2-agonists, inhaled corticosteroids,
anticholinergics and short-acting beta2-agonists were discontinued. Subjects were is-
sued with either a VENTOLIN DISKUS/ACCUHALER inhaler (200 µg/actuation)
or VENTOLIN MDI (100 µg/actuation) plus VOLUMATIC spacer for use as relief
medication
Participants Population: 125 adults with a clinical history of moderate to severe COPD as defined
by the Global Initiative for Obstructive Lung Disease 2001 guidelines
Inclusion Criteria: Aged 40-80 years inclusive. Post-bronchodilator FEV1 less than
70% of predicted normal. Subjects must have had a smoking history (current or former
smokers) of more than 10 pack-years. Mean FEV1 1.4 L.
Exclusion Criteria: Within four weeks prior to visit one; COPD exacerbation; received
oral, parenteral, or depot corticosteroids for a COPD exacerbation; received antibiotic
therapy and/or been hospitalised for either a lower respiratory tract infection or for
COPD exacerbation, or had any changes in their COPD medication
Interventions 1. Combination of fluticasone 500 µg and salmeterol 50 µg twice a day via DISKUS
inhaler plus placebo capsules to match TIO delivered once daily via the Handihaler
inhaler.
2. Tiotropium 18 µg once a day via Handihaler plus placebo to match FPS
DISKUS combination product delivered twice daily.
Outcomes No primary outcomes as this was an exploratory study.
Notes Sponsored by GlaxoSmithKline.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “At randomisation (Visit 2/2A) all eligible
subjects were randomly assigned to treat-
ment by use of a Registration and Mate-
rial Ordering System (RAMOS) which uti-
lized an IVRS developed by GSK. Subjects
were assigned to a unique treatment num-
ber.” “Randomallocation to study drugwas
stratified according to smoking status of
subjects at entry (current smoker, former
smoker) on a 1:1 basis.”
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SCO40034 (Continued)
Allocation concealment (selection bias) Low risk “The treatment number was an identifica-
tion number for the blinded study medi-
cation and was assigned from a randomi-
sation schedule provided by GSK. This
schedule was generated by a GSK ran-
domisation program, Patient Allocation for
Clinical Trials (PACT) and then stored in
another GSK program known as RandAll.
Treatment numbers were not assigned to a
subject without contacting RAMOS, and
once a treatment number hadbeen assigned
to a subject, it was not reassigned to an-
other subject in this study.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double blind double dummy.”
There was a difference between the active
tiotropium bromide and matching placebo
capsules. Therefore someone who was not
directly involved in the study received and
documented all returned medication in a
drug accountability log, a separate account-
ability log was maintained for each subject
and subjects administered their own study
medication without the investigator or site
personnel being present
Subjects were unblinded only when knowl-
edge of the treatment was essential for
the clinical management or welfare of
the subject. Cases of unblinding were
to be reported and documented immedi-
ately. Pateients experiencing serious adverse
events were unblinded.Decisions by the in-
vestigator towithdraw the subject due to an
AE were made before unblinding. Blinded
study drug was supplied in treatment packs
at Visits 2/2A, 4 and 5. The content of each
treatment pack was detailed on the outer
packaging
Incomplete outcome data (attrition bias)
All outcomes
High risk 117/125 (94%) Completed the study, but
withdrawals were imbalanced with one
from the FPS arm and seven from the
tiotropium arm
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bateman 2008 This pilot study compared separate fluticasone and salmeterol inhalers to tiotropium
Golabi 2006 Study of cross-over design.
Hara 2007 Study of cross-over design.
Singh 2008 Study of cross-over design.
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D A T A A N D A N A L Y S E S
Comparison 1. Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality (All-cause) 3 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
2 Hospital Admission 3 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
2.1 Hospital admissions all
cause
3 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Hospital admissions
resulting from exacerbations
1 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Exacerbations (all cause): number
of patients experiencing one or
more exacerbations over two
years
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Exacerbations (mean number of
exacerbations per patient per
year)
1 Rate Ratio (Fixed, 95% CI) Totals not selected
4.1 Exacerbations (all cause) 1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Exacerbations requiring
oral corticosteroids
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Exacerbations requiring
antibiotics
1 Rate Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Pneumonia 3 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
6 Quality of Life 1 Mean Difference (Fixed, 95% CI) Totals not selected
6.1 32 weeks 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 104 weeks 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
7 FEV1 (Litres) 3 Mean Difference (Fixed, 95% CI) Totals not selected
7.1 FEV1 at short time frame
(3 to 12 weeks)
3 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 FEV1 at 2 years 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Serious Adverse Events
(non-fatal)
3 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
9 Adverse Events 3 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
10 Withdrawal 3 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
10.1 Total number of subjects
withdrawn
3 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 Due to adverse events 3 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 Due to lack of efficacy 3 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio), Outcome 1 Mortality
(All-cause).
Review: Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
Comparison: 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio)
Outcome: 1 Mortality (All-cause)
Study or subgroup FPS Tio
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
INSPIRE 21/658 38/665 0.55 [ 0.33, 0.93 ]
Dawber 2005 0/28 0/27 0.0 [ 0.0, 0.0 ]
SCO40034 0/61 0/64 0.0 [ 0.0, 0.0 ]
0.5 0.7 1 1.5 2
Favours FPS Favours Tio
Analysis 1.2. Comparison 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio), Outcome 2 Hospital
Admission.
Review: Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
Comparison: 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio)
Outcome: 2 Hospital Admission
Study or subgroup FPS Tio
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Hospital admissions all cause
INSPIRE 215/658 179/665 1.32 [ 1.04, 1.67 ]
Dawber 2005 1/28 0/27 7.13 [ 0.14, 359.55 ]
SCO40034 1/61 2/64 0.53 [ 0.05, 5.22 ]
2 Hospital admissions resulting from exacerbations
INSPIRE 105/658 86/665 1.28 [ 0.94, 1.74 ]
0.005 0.1 1 10 200
Favours FPS Favours Tio
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Analysis 1.3. Comparison 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio), Outcome 3
Exacerbations (all cause): number of patients experiencing one or more exacerbations over two years.
Review: Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
Comparison: 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio)
Outcome: 3 Exacerbations (all cause): number of patients experiencing one or more exacerbations over two years
Study or subgroup FPS Tio Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
INSPIRE 408/658 393/665 1.13 [ 0.91, 1.41 ]
0.5 0.7 1 1.5 2
Favours FPS Favours Tio
Analysis 1.4. Comparison 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio), Outcome 4
Exacerbations (mean number of exacerbations per patient per year).
Review: Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
Comparison: 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio)
Outcome: 4 Exacerbations (mean number of exacerbations per patient per year)
Study or subgroup log [Rate Ratio] Rate Ratio Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exacerbations (all cause)
INSPIRE -0.03 (0.0745) 0.97 [ 0.84, 1.12 ]
2 Exacerbations requiring oral corticosteroids
INSPIRE -0.211 (0.1) 0.81 [ 0.67, 0.99 ]
3 Exacerbations requiring antibiotics
INSPIRE 0.174 (0.077) 1.19 [ 1.02, 1.38 ]
0.5 0.7 1 1.5 2
Favours FPS Favours Tio
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Analysis 1.5. Comparison 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio), Outcome 5 Pneumonia.
Review: Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
Comparison: 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio)
Outcome: 5 Pneumonia
Study or subgroup FPS Tio
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
INSPIRE 50/658 24/665 2.13 [ 1.33, 3.40 ]
Dawber 2005 1/28 0/27 7.13 [ 0.14, 359.55 ]
SCO40034 0/61 0/64 0.0 [ 0.0, 0.0 ]
0.001 0.01 0.1 1 10 100 1000
Favours FPS Favours Tio
Analysis 1.6. Comparison 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio), Outcome 6 Quality of
Life.
Review: Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
Comparison: 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio)
Outcome: 6 Quality of Life
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 32 weeks
INSPIRE -1.92 (0.83) -1.92 [ -3.55, -0.29 ]
2 104 weeks
INSPIRE -2.07 (0.995) -2.07 [ -4.02, -0.12 ]
-4 -2 0 2 4
Favours FPS Favours Tio
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Analysis 1.7. Comparison 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio), Outcome 7 FEV1
(Litres).
Review: Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
Comparison: 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio)
Outcome: 7 FEV1 (Litres)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 FEV1 at short time frame (3 to 12 weeks)
INSPIRE -0.02 (0.015) -0.02 [ -0.05, 0.01 ]
Dawber 2005 0.091 (0.076) 0.09 [ -0.06, 0.24 ]
SCO40034 0.02 (0.043) 0.02 [ -0.06, 0.10 ]
2 FEV1 at 2 years
INSPIRE -0.02 (0.0178) -0.02 [ -0.05, 0.01 ]
-0.2 -0.1 0 0.1 0.2
Favours Tio Favours FPS
Analysis 1.8. Comparison 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio), Outcome 8 Serious
Adverse Events (non-fatal).
Review: Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
Comparison: 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio)
Outcome: 8 Serious Adverse Events (non-fatal)
Study or subgroup FPS Tio
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Dawber 2005 1/28 0/27 7.13 [ 0.14, 359.55 ]
INSPIRE 194/658 141/665 1.55 [ 1.21, 1.98 ]
SCO40034 1/61 2/64 0.53 [ 0.05, 5.22 ]
0.02 0.1 1 10 50
Favours FPS Favours Tio
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Analysis 1.9. Comparison 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio), Outcome 9 Adverse
Events.
Review: Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
Comparison: 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio)
Outcome: 9 Adverse Events
Study or subgroup FPS Tio
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
INSPIRE 435/658 414/665 1.18 [ 0.94, 1.48 ]
Dawber 2005 10/28 4/27 2.95 [ 0.89, 9.81 ]
SCO40034 35/61 34/64 1.19 [ 0.59, 2.39 ]
0.2 0.5 1 2 5
Favours FPS Favours Tio
Analysis 1.10. Comparison 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio), Outcome 10
Withdrawal.
Review: Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
Comparison: 1 Fluticasone/Salmeterol (FPS) versus Tiotropium (Tio)
Outcome: 10 Withdrawal
Study or subgroup Fluticasone/Salmeterol Tiotropium
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Total number of subjects withdrawn
INSPIRE 232/658 279/665 0.75 [ 0.60, 0.94 ]
Dawber 2005 1/28 0/27 7.13 [ 0.14, 359.55 ]
SCO40034 1/61 7/64 0.21 [ 0.05, 0.89 ]
2 Due to adverse events
INSPIRE 67/658 66/665 1.03 [ 0.72, 1.47 ]
Dawber 2005 1/28 0/27 7.13 [ 0.14, 359.55 ]
SCO40034 0/61 2/64 0.14 [ 0.01, 2.26 ]
3 Due to lack of efficacy
0.002 0.1 1 10 500
Favours FPS Favours Tio
(Continued . . . )
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(. . . Continued)
Study or subgroup Fluticasone/Salmeterol Tiotropium
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
INSPIRE 32/658 38/665 0.84 [ 0.52, 1.37 ]
Dawber 2005 0/28 0/27 0.0 [ 0.0, 0.0 ]
SCO40034 0/61 2/64 0.14 [ 0.01, 2.26 ]
0.002 0.1 1 10 500
Favours FPS Favours Tio
A D D I T I O N A L T A B L E S
Table 1. Differences in the reported cases of pneumonia in the INSPIRE trial
Pneumonias recorded in patients treated
with fluticasone/salmeterol
number (%)
Pneumonias recorded in patients treated
with tiotropium
number (%)
Most frequent adverse effects on ITT
population*
43 (7) 23 (3)
Serious adverse events* 37 (6) 22 (3)
Fatal serious adverse events* 3 (<1) 0
Adverse events including pneumonia, lo-
bar pneumonia and bronchopneumo-
nia**
50 (8) 24 (4)
* reported in SCO40035
** reported in Wedzicha 2008
Table 2. Reasons for withdrawals from INSPIRE
Reason for withdrawal Fluticasone/Salmeterol Tiotropium
Adverse event 67 66
‘Withdrew consent 61 82
Lost to follow-up 15 13
Protocol violation 7 8
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Table 2. Reasons for withdrawals from INSPIRE (Continued)
Failed entry criteria 0 3
COPD exacerbation 37 51
Lack of efficacy 32 38
Other 13 17
Missing 0 1
Total 232 (35.3%) 279 (42.0%)
Table 3. Proportion of participants developing pneumonia
Study Pneumonia on
FPS
Comparison
treatment
Pneumo-
nia on compari-
son treatment
Trial duration,
weeks
Pneumo-
nia on FPS per
52 weeks
Pneumomia on
comparison per
52 weeks
Naninni 2007a† 325/2673 (12%) Placebo 194/2556 (8%) 105* 5.9% 4.0%
TORCH 303/1546 (20%) Placebo 164/1544 (11%) 156 6.7% 3.7%
Naninni 2007b† 337/3334 (10%) LABA 226/3329 (7%) 92* 5.7% 4.0%
TORCH 303/1546 (20%) LABA 205/1542 (13%) 156 6.7% 4.3%
INSPIRE 50/658 (8%) Tiotropium 24/665 (4%) 104 3.8% 1.8%
†Includes data from TORCH
*Weighted mean trial duration
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A P P E N D I C E S
Appendix 1. Definition of Serious Adverse Events
The Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use (ICH) define serious adverse events as follows (ICHE2a 1995):
“A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose:
• Results in death,
• Is life-threatening,
• Requires inpatient hospitalisation or prolongation of existing hospitalisation,
• Results in persistent or significant disability/incapacity, or
• Is a congenital anomaly/birth defect.
NOTE: The term ”life-threatening“ in the definition of ”serious“ refers to an event in which the patient was at risk of death at the time
of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.”
F E E D B A C K
Clarification on mortality data and analysis of exacerbation rates requested, 10 January 2011
Summary
We have read this important review with great interest. In our assessment of the review we have several questions/comments.
1. It is stated that the INSPIRE trial investigators did not collect outcome events for patients who withdrew during the course of
the study. We looked at the original INSPIRE publication (Wedzicha 2008) to confirm that this was the case. The INSPIRE
investigators state “Mortality data was not collected after patients withdrew from therapy as in the TORCH (Toward a Revolution in
COPD Health) study.” This does not specifically state that other outcome events such as exacerbations were not collected for patients
who withdrew prematurely. We wanted to know if this point was clarified with Wedzicha et al. We had assumed exacerbations were
collected if they occurred after withdrawal but now we are not sure. Your help would be greatly appreciated.
2. For the INSPIRE trial rate ratios (RR) are given for the exacerbation analyses. We are not sure that sufficient explanations were
given as to the difference in interpretation between rate ratios and relative risk ratios. This would be useful for clinician readers to
know.
3. We congratulate the authors of this review for stating that conclusions are difficult to draw when there is so much missing data.
Reply
1. We did not confirm whether or not the trialists collected data on outcomes other than mortality in patients who withdrew
therapy with the trialists before publication of this systematic review. Since receiving this feedback, we have been in contact with the
pharmaceutical company who confirmed that there was no follow-up of patents if they withdrew form the study for other outcome
data such as exacerbations. Because patents were followed up until the resolution of a serious adverse event, there is some limited
mortality data for deaths which occurred after cessation of treatment which the trialist confirmed was reported in the original
publication and therefore this review.
2. The main difference between Rate Ratios and Risk Ratios (or Odds Ratios), is that Rate Ratios include multiple exacerbations
from individual patients, whereas the unit of analysis for Risk and Odds ratios is patients with one or more exacerbations. We have
now included a forest plot to indicate the result achieved using Odds Ratios and have added a discussion around the differences in
reporting is included in the Discussion section.
We thank Aaron and Elsa for their comments, in particular the second comment which allowed us to explain the issue of rate ratio
versus relative risk ratios within our review
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Last assessed as up-to-date: 7 October 2009.
Date Event Description
1 June 2011 Feedback has been incorporated We included an analysis of exacerbations using odds ratios and compared this to
the rate ratio analysis we originally presented. Please see Discussion and Feedback.
1 June 2011 Amended Feedback incorporated
H I S T O R Y
Protocol first published: Issue 3, 2009
Review first published: Issue 5, 2010
C O N T R I B U T I O N S O F A U T H O R S
Studies were assessed by CJC and EJW. CJC and EJW extracted data and entered it into RevMan, conducted the analysis. EJW wrote
the review with input from CJC, & PP.
CJC and PP developed the protocol.
Toby Lasserson was an author on the protocol but is not an author on the review.
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28Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Internal sources
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• NIHR Programme Grant, UK.
Financial Support
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We changed some of the primary and secondary outcomes from those stated in the protocol:
• “Exacerbations requiring antibiotics or short burst oral corticosteroids as defined by agreed criteria” was changed to
“Exacerbations; all cause, requiring short burst oral corticosteroids or antibiotics as defined by agreed criteria”. We felt it was helpful
to include data for the total number of exacerbations and this reflected the data reported in INSPIRE
• In addition to all cause hospital admissions, we included data for exacerbations resulting in hospital admissions to reflect the
primary outcome of INSPIRE
• We added withdrawal as a secondary outcome because the high and differential withdrawal rate was important
Exacerbations, quality of life and FEV1 data were entered using generic inverse variance because the data presented in the study report
required it.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Inhalation; Adrenergic beta-Agonists [∗administration & dosage]; Albuterol [administration & dosage; analogs &
derivatives]; Androstadienes [administration & dosage]; Bronchodilator Agents [∗administration & dosage]; Drug Therapy, Combina-
tion [methods]; Patient Dropouts [statistics & numerical data]; Pneumonia [drug therapy]; Pulmonary Disease, Chronic Obstructive
[∗drug therapy; mortality]; Scopolamine Derivatives [∗administration & dosage]
MeSH check words
Humans
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